Highlights from todays's article :
- "The first thing that needs to be done before anything else is diagnosis without an autopsy. Without diagnosis during life, there can be no treatment. Aethlon Medical Inc. (AEMD) has taken the lead on that front, partnered with Eli Lilly (NYSE:LLY) subsidiary Avid Radiopharmaceuticals."
- Aethlon's Exosome Sciences is conducting Alzheimer's and CTE diagnostic tests. The company has just completed a phase 2 study of its experimental biomarker, TauSome, to investigate its efficacy as a blood based test to diagnose CTE. The trial was conducted in collaboration with the Boston University CTE research center, which recently completed a separate study in which it investigated CTE prevalence in the brains of 91 former NFL players post mortem. The study found CTE in 96% of brains tested - 87 out of the 91 - suggesting CTE has a much higher incidence rate among NFL players than previously thought.
- We are yet to hear full topline data, but the trial is completed. A good hint of what we'll see with the full data comes from lead physician Dr. Robert Stern who is conducting the trial. He has stated that the tausome level is much higher in the former NFL group than the control group, and that the level of tau present correlates with the severity of memory loss.
- Since there is no current diagnosis tool available for CTE, if Exosome can get its candidate approved, it would be the only player in a large market of retired athletes. Going forward, this could bode well for Aethlon, making the latter an intriguing exposure especially given that a pivotal phase 2 trial is already completed.
